The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects
Introduction: Obese insulin-resistant individuals exhibit a dyslipidaemia due to raised levels of both hepatically and intestinally derived lipoproteins. However, little is known about the related dysregulation of intestinally derived lipoproteins. We examined whether the insulin-sensitizing agents,...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
Blackwell
2005
|
| Online Access: | http://hdl.handle.net/20.500.11937/42091 |
| _version_ | 1848756324624498688 |
|---|---|
| author | James, Anthony Watts, G. Mamo, John |
| author_facet | James, Anthony Watts, G. Mamo, John |
| author_sort | James, Anthony |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Introduction: Obese insulin-resistant individuals exhibit a dyslipidaemia due to raised levels of both hepatically and intestinally derived lipoproteins. However, little is known about the related dysregulation of intestinally derived lipoproteins. We examined whether the insulin-sensitizing agents, metformin and rosiglitazone, improve intestinal lipoprotein metabolism in obese insulin-resistant individuals. Methods: Thirty male obese (body mass index > 26; waist circumference > 100 cm) insulin-resistant [homeostasis model assessment (HOMA) score > 2.0] subjects were randomized to either a metformin (1 g bd), rosiglitazone (4 mg bd) or control treatment group for a period of 8 weeks. Fasting and postprandial lipid metabolism was studied before and after the intervention period. Results: Metformin and rosiglitazone both significantly improved insulin sensitivity, but this was not paralleled by improvement in dyslipidaemia. With rosiglitazone relative to control there was a significant (p < 0.05) increase in the area under the apolipoprotein (apo) B48 curve following the oral fat load and a decrease in the ratio of triglyceride to apo B48 levels postprandially following rosiglitazone treatment. Conclusion: In obese insulin-resistant subjects metformin and rosiglitazone both improve insulin sensitivity, as measured by HOMA, without improvement in lipid metabolism. Rosiglitazone may have a detrimental effect on chylomicron metabolism by an increase in postprandial apo B48 levels, and this requires further investigation. |
| first_indexed | 2025-11-14T09:10:24Z |
| format | Journal Article |
| id | curtin-20.500.11937-42091 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:10:24Z |
| publishDate | 2005 |
| publisher | Blackwell |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-420912017-09-13T16:01:01Z The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects James, Anthony Watts, G. Mamo, John Introduction: Obese insulin-resistant individuals exhibit a dyslipidaemia due to raised levels of both hepatically and intestinally derived lipoproteins. However, little is known about the related dysregulation of intestinally derived lipoproteins. We examined whether the insulin-sensitizing agents, metformin and rosiglitazone, improve intestinal lipoprotein metabolism in obese insulin-resistant individuals. Methods: Thirty male obese (body mass index > 26; waist circumference > 100 cm) insulin-resistant [homeostasis model assessment (HOMA) score > 2.0] subjects were randomized to either a metformin (1 g bd), rosiglitazone (4 mg bd) or control treatment group for a period of 8 weeks. Fasting and postprandial lipid metabolism was studied before and after the intervention period. Results: Metformin and rosiglitazone both significantly improved insulin sensitivity, but this was not paralleled by improvement in dyslipidaemia. With rosiglitazone relative to control there was a significant (p < 0.05) increase in the area under the apolipoprotein (apo) B48 curve following the oral fat load and a decrease in the ratio of triglyceride to apo B48 levels postprandially following rosiglitazone treatment. Conclusion: In obese insulin-resistant subjects metformin and rosiglitazone both improve insulin sensitivity, as measured by HOMA, without improvement in lipid metabolism. Rosiglitazone may have a detrimental effect on chylomicron metabolism by an increase in postprandial apo B48 levels, and this requires further investigation. 2005 Journal Article http://hdl.handle.net/20.500.11937/42091 10.1111/j.1463-1326.2004.00407.x Blackwell restricted |
| spellingShingle | James, Anthony Watts, G. Mamo, John The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects |
| title | The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects |
| title_full | The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects |
| title_fullStr | The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects |
| title_full_unstemmed | The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects |
| title_short | The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects |
| title_sort | effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects |
| url | http://hdl.handle.net/20.500.11937/42091 |